APA (7th ed.) Citation

SL, D., SG, E., JR, D., WA, M., A, D., CD, W., . . . S, L. (2018). A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. The oncologist, 23(12), 1409. https://doi.org/10.1634/theoncologist.2018-0315

Chicago Style (17th ed.) Citation

SL, Davis, et al. "A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer." The Oncologist 23, no. 12 (2018): 1409. https://doi.org/10.1634/theoncologist.2018-0315.

MLA (9th ed.) Citation

SL, Davis, et al. "A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer." The Oncologist, vol. 23, no. 12, 2018, p. 1409, https://doi.org/10.1634/theoncologist.2018-0315.